The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Journal of Health Economics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1007/s10198-007-0091-0PMID 18157559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK

  2012cited by this paper
• An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis

  2012cited by this paper
• Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study.

  2008cited by this paper
• HOW TO UNDERSTAND THEM

  2008cited by this paper
• Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

  2008cited by this paper
• Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

  2007cited by this paper
• Not all "quality-adjusted life years" are equal.

  2007cited by this paper
• Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components.

  2006cited by this paper
• Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

  2006cited by this paper
• Costs in rheumatology: results and lessons learned from the ‘Hannover Costing Study’

  2006cited by this paper
• Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

  2006cited by this paper
• Health economic issues in rheumatoid arthritis

  2006cited by this paper
• Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

  2005influential reference
• Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.

  2005influential reference
• Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

  2005cited by this paper
• A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.

  2005cited by this paper
• Analytic Choices in Economic Models of Treatments for Rheumatoid Arthritis: What Makes a Difference?

  2005influential reference
• Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

  2004influential reference
• Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

  2004cited by this paper
• The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

  2004cited by this paper
• Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations.

  2004cited by this paper
• GAIN OF FUNCTION ANKH VARIANTS CAUSE BOTH FAMILIAL AND SPORADIC CALCIUM PYROPHOSPHATE DIHYDRATE CHONDROCALCINOSIS

  2004influential reference
• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

  2004influential reference
• Do rheumatology cost-effectiveness analyses make sense?

  2004cited by this paper
• The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.

  2003influential reference
• Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

  2003cited by this paper
• Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.

  2003cited by this paper
• TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

  2003influential reference
• A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.

  2002influential reference
• Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.

  2002cited by this paper
• The estimation of a preference-based measure of health from the SF-36.

  2002cited by this paper
• Modelling the costs and effects of leflunomide in rheumatoid arthritis

  2002cited by this paper
• A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia

  2002cited by this paper
• The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis.

  2002cited by this paper
• Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

  2002cited by this paper
• Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity.

  2001cited by this paper
• Long-term morbidity, mortality, and economics of rheumatoid arthritis.

  2001cited by this paper
• Premature mortality in patients with rheumatoid arthritis: evolving concepts.

  2001cited by this paper
• Total Mortality is Increased in Rheumatoid Arthritis. A 17-Year Prospective Study

  2001cited by this paper
• The links between joint damage and disability in rheumatoid arthritis.

  2000cited by this paper
• A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

  2000cited by this paper
• Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis*

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.

  1999cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

  1999cited by this paper
• Economic consequences of the progression of rheumatoid arthritis in Sweden.

  1999cited by this paper
• Disability in patients with early inflammatory polyarthritis cannot be "tracked" from year to year: an examination of the hypothesis underlying percentile reference charts.

  1999cited by this paper
• Etanercept Therapy in Rheumatoid Arthritis

  1999cited by this paper
• Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial

  1999cited by this paper
• The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients.

  1998cited by this paper
• Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well.

  1998cited by this paper
• The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.

  1997cited by this paper
• Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

  1997cited by this paper
• Quality of life and health economics: where is the link?

  1996cited by this paper
• A social tariff for EuroQol: results from a UK general population survey

  1995cited by this paper
• The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups.

  1994cited by this paper
• The mortality of rheumatoid arthritis.

  1994cited by this paper
• The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs

  1993cited by this paper
• Functional disability in rheumatoid arthritis: two different models in early and established disease.

  1992cited by this paper
• EuroQol--a new facility for the measurement of health-related quality of life.

  1990cited by this paper
• EuroQol : a new facility for the measurement of health-related quality of life

  1990cited by this paper
• The cost effectiveness of auranofin: results of a randomized clinical trial.

  1988cited by this paper
• Measurement of health state utilities for economic appraisal.

  1986cited by this paper
• Measurement of patient outcome in arthritis.

  1980cited by this paper

• Research trends in contemporary health economics: a scientometric analysis on collective content of specialty journals

  2024cites this paper
• Advancing rheumatic disease treatment: A journey towards better lives

  2024cites this paper
• Signaling pathways in rheumatoid arthritis: implications for targeted therapy

  2023cites this paper
• Physical Exercise and Occupational Therapy at Home to Improve the Quality of Life in Subjects Affected by Rheumatoid Arthritis: A Randomized Controlled Trial

  2023cites this paper
• Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review

  2019cites this paper
• Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece

  2019cites this paper
• An enhanced RRM2 siRNA delivery to rheumatoid arthritis fibroblast-like synoviocytes through a liposome-protamine-DNA-siRNA complex with cell permeable peptides

  2018cites this paper
• EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry

  2017cites this paper
• Cost Analysis of Biologic Drugs in Rheumatoid Arthritis First Line Treatment After Methotrexate Failure According to Patients’ Body Weight

  2016cites this paper
• Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight.

  2016cites this paper
• Measuring the economic value of morning stiffness: consistency over 1 year

  2016cites this paper
• Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry

  2016cites this paper
• Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model

  2015cites this paper
• Access to an optimal treatment. Current situation

  2015cites this paper
• Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries

  2015cites this paper
• Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists

  2014cites this paper
• Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

  2014cites this paper
• Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs

  2014cites this paper
• Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

  2014cites this paper
• The REMIRA (REMission in RA) study : defining Low Disease Activity (LDA) states using clinical, imaging and biological measures in Rheumatoid Arthritis

  2014cites this paper
• Recommandations de la Société Marocaine de Rhumatologie pour la prise en charge de la polyarthrite rhumatoïde : mise à jour du référentiel de 2011.

  2014cites this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

  2013cites this paper
• A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis

  2013cites this paper
• FRI0542 Preferences of maltese patients with rheumatic diseases for information on drug adverse events and shared decision making

  2013cites this paper
• antirheumatic drugs: 2013 update synthetic and biological disease-modifying management of rheumatoid arthritis with EULAR recommendations for the

  2013cites this paper
• Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients

  2012cites this paper
• Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.

  2012cites this paper
• Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.

  2012cites this paper
• Musculoskeletal Disorders and Health Behaviors Among U.S. Workers

  2011influential citation
• How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis?

  2011cites this paper
• Economic consequences and potential benefits.

  2011cites this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cites this paper
• Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study.

  2010cites this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

  2010cites this paper
• Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

  2010cites this paper
• Chapter 32 – Economic Considerations in the Treatment of Rheumatic Diseases

  2010cites this paper
• Future challenges for health economics and health technology assessment of biological drugs

  2010cites this paper
• Developments in the clinical understanding of rheumatoid arthritis

  2009cites this paper
• Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data

  2009cites this paper
• Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment

  2009cites this paper
• Unterversorgung mit innovativen Therapien bei der rheumatoiden Arthritis

  2008cites this paper
• Clinicoeconomics and Outcomes Research Dovepress Costs Associated with Rheumatoid Arthritis in Italy: Past, Present, and Future

  year unknowncites this paper